Skip to content
10-Q

Quarterly Report

ANADYS PHARMACEUTICALS INC

0000950123-11-074889

← back to feed
Filed
Aug 9, 2011 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2011 · Aug 4, 2011 57.18M sh
Capex Q2 2011 · Jun 30, 2011 $30K
Capex Q2 2011 · Jun 30, 2010 $7K
Operating Cash Flow Q2 2011 · Jun 30, 2011 −$11.91M
Operating Cash Flow Q2 2011 · Jun 30, 2010 −$9.62M
Cash And Equivalents Q2 2011 · Jun 30, 2011 $2.05M
Cash And Equivalents Q2 2011 · Dec 31, 2010 $7.62M
Cash And Equivalents Q2 2011 · Jun 30, 2010 $9.44M
Cash And Equivalents Q2 2011 · Dec 31, 2009 $4.5M
Stockholders Equity Q2 2011 · Jun 30, 2011 $21.51M
Stockholders Equity Q2 2011 · Dec 31, 2010 $34.67M
Current Liabilities Q2 2011 · Jun 30, 2011 $5.82M
Current Liabilities Q2 2011 · Dec 31, 2010 $4.85M
Current Assets Q2 2011 · Jun 30, 2011 $27.21M
Current Assets Q2 2011 · Dec 31, 2010 $39.3M
Total Assets Q2 2011 · Jun 30, 2011 $27.34M
Total Assets Q2 2011 · Dec 31, 2010 $39.54M
Sga Expense Q2 2011 · Jun 30, 2011 $1.51M
Sga Expense Q2 2011 · Jun 30, 2011 $3.07M
Sga Expense Q2 2011 · Jun 30, 2010 $1.6M
Sga Expense Q2 2011 · Jun 30, 2010 $3.24M
Rd Expense Q2 2011 · Jun 30, 2011 $7.03M
Rd Expense Q2 2011 · Jun 30, 2011 $12.01M
Rd Expense Q2 2011 · Jun 30, 2010 $3.06M
Rd Expense Q2 2011 · Jun 30, 2010 $6.79M
Net Income Q2 2011 · Jun 30, 2011 −$8.12M
Net Income Q2 2011 · Jun 30, 2011 −$14.07M
Net Income Q2 2011 · Jun 30, 2010 −$2.98M
Net Income Q2 2011 · Jun 30, 2010 −$9.18M